R-DHAP

DRUG3 trials

Sponsors

Fondazione Italiana Linfomi - ETS, Stichting Hemato-Oncologie voor Volwassenen Nederland

Conditions

DLBCLDiffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma RecurrentDiffuse Large B-cell Lymphoma Refractory

Phase 1

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

RecruitingNCT03356054

Stichting Hemato-Oncologie voor Volwassenen NederlandDLBCL

Start: 2018-03-05End: 2027-02-28Target: 37Updated: 2020-12-10

Phase 2

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

CompletedNCT01805557

Fondazione Italiana Linfomi - ETSDiffuse Large B-cell Lymphoma Recurrent, Diffuse Large B-cell Lymphoma Refractory

Start: 2013-02-04End: 2020-11-20Updated: 2022-06-08

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

WithdrawnNCT05966233

Fondazione Italiana Linfomi - ETSDiffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory

Start: 2024-01-31End: 2029-01-31Updated: 2024-05-21

Related Papers

S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12

HemaSphere2022-06-01

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood2019-11-13